APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drug Safety and Pharmacovigilance Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Safety and Pharmacovigilance Service Market Outlook and Growth Opportunities 2026

Report ID 174123190416 January 2026195 pages

Choose your research edition.

Industry ResearchDrug Safety and Pharmacovigilance Service Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Safety and Pharmacovigilance Service Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Drug Safety and Pharmacovigilance Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Safety and Pharmacovigilance Service Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Safety and Pharmacovigilance Service Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Drug Safety and Pharmacovigilance Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Safety and Pharmacovigilance Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Safety and Pharmacovigilance Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Safety and Pharmacovigilance Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Safety and Pharmacovigilance Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Safety and Pharmacovigilance Service market include BioPoint, Cmed, Drug Safety Solutions, Hilbrans, Orbis Clinical, Parexel, PharmaLex, ProPharma and SGS, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Safety and Pharmacovigilance Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Safety and Pharmacovigilance Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Safety and Pharmacovigilance Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Safety and Pharmacovigilance Service market.

Drug Safety and Pharmacovigilance Service Segment by Company

BioPoint

Cmed

Drug Safety Solutions

Hilbrans

Orbis Clinical

Parexel

PharmaLex

ProPharma

SGS

SJ Pharma Consulting LLC

Vitrana

X7 Research

Drug Safety and Pharmacovigilance Service Segment by Type

Drug Safety Service

Drug Pharmacovigilance Service

Drug Safety and Pharmacovigilance Service Segment by Application

Experimental Stage

Clinical Stage

Postmarketing Stage

Other

Drug Safety and Pharmacovigilance Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Safety and Pharmacovigilance Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Safety and Pharmacovigilance Service key companies, revenue, market share, and recent developments.

3. To split the Drug Safety and Pharmacovigilance Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Safety and Pharmacovigilance Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Safety and Pharmacovigilance Service significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Safety and Pharmacovigilance Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Safety and Pharmacovigilance Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Safety and Pharmacovigilance Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Safety and Pharmacovigilance Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Safety and Pharmacovigilance Service industry.

Chapter 3: Detailed analysis of Drug Safety and Pharmacovigilance Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Safety and Pharmacovigilance Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Safety and Pharmacovigilance Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Safety and Pharmacovigilance Service Industry Trends Table 2. Drug Safety and Pharmacovigilance Service Industry Drivers Table 3. Drug Safety and Pharmacovigilance Service Industry Opportunities and Challenges Table 4. Drug Safety and Pharmacovigilance Service Industry Restraints Table 5. Global Drug Safety and Pharmacovigilance Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Safety and Pharmacovigilance Service Revenue Share by Company (2021-2026) Table 7. Global Drug Safety and Pharmacovigilance Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Safety and Pharmacovigilance Service Key Company Manufacturing Base & Headquarters Table 9. Global Drug Safety and Pharmacovigilance Service Company, Product Type & Application Table 10. Global Drug Safety and Pharmacovigilance Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Safety and Pharmacovigilance Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drug Safety Service Table 15. Significant Companies of Drug Pharmacovigilance Service Table 16. Global Drug Safety and Pharmacovigilance Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Drug Safety and Pharmacovigilance Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Drug Safety and Pharmacovigilance Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Type (2021-2026) Table 20. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Experimental Stage Table 22. Significant Companies of Clinical Stage Table 23. Significant Companies of Postmarketing Stage Table 24. Significant Companies of Other Table 25. Global Drug Safety and Pharmacovigilance Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drug Safety and Pharmacovigilance Service Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drug Safety and Pharmacovigilance Service Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Application (2021-2026) Table 29. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Application (2027-2032) Table 30. Global Drug Safety and Pharmacovigilance Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drug Safety and Pharmacovigilance Service Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Region (2021-2026) Table 33. Global Drug Safety and Pharmacovigilance Service Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Region (2027-2032) Table 35. Global Drug Safety and Pharmacovigilance Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drug Safety and Pharmacovigilance Service Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drug Safety and Pharmacovigilance Service Sales Value Market Share by Country (2021-2026) Table 38. Global Drug Safety and Pharmacovigilance Service Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drug Safety and Pharmacovigilance Service Sales Value Market Share by Country (2027-2032) Table 40. BioPoint Company Information Table 41. BioPoint Business Overview Table 42. BioPoint Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. BioPoint Drug Safety and Pharmacovigilance Service Product Portfolio Table 44. BioPoint Recent Development Table 45. Cmed Company Information Table 46. Cmed Business Overview Table 47. Cmed Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Cmed Drug Safety and Pharmacovigilance Service Product Portfolio Table 49. Cmed Recent Development Table 50. Drug Safety Solutions Company Information Table 51. Drug Safety Solutions Business Overview Table 52. Drug Safety Solutions Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Drug Safety Solutions Drug Safety and Pharmacovigilance Service Product Portfolio Table 54. Drug Safety Solutions Recent Development Table 55. Hilbrans Company Information Table 56. Hilbrans Business Overview Table 57. Hilbrans Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Hilbrans Drug Safety and Pharmacovigilance Service Product Portfolio Table 59. Hilbrans Recent Development Table 60. Orbis Clinical Company Information Table 61. Orbis Clinical Business Overview Table 62. Orbis Clinical Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Orbis Clinical Drug Safety and Pharmacovigilance Service Product Portfolio Table 64. Orbis Clinical Recent Development Table 65. Parexel Company Information Table 66. Parexel Business Overview Table 67. Parexel Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Parexel Drug Safety and Pharmacovigilance Service Product Portfolio Table 69. Parexel Recent Development Table 70. PharmaLex Company Information Table 71. PharmaLex Business Overview Table 72. PharmaLex Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. PharmaLex Drug Safety and Pharmacovigilance Service Product Portfolio Table 74. PharmaLex Recent Development Table 75. ProPharma Company Information Table 76. ProPharma Business Overview Table 77. ProPharma Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. ProPharma Drug Safety and Pharmacovigilance Service Product Portfolio Table 79. ProPharma Recent Development Table 80. SGS Company Information Table 81. SGS Business Overview Table 82. SGS Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. SGS Drug Safety and Pharmacovigilance Service Product Portfolio Table 84. SGS Recent Development Table 85. SJ Pharma Consulting LLC Company Information Table 86. SJ Pharma Consulting LLC Business Overview Table 87. SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Product Portfolio Table 89. SJ Pharma Consulting LLC Recent Development Table 90. Vitrana Company Information Table 91. Vitrana Business Overview Table 92. Vitrana Drug Safety and Pharmacovigilance Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Vitrana Drug Safety and Pharmacovigilance Service Product Portfolio Table 94. Vitrana Recent Development Table 95. X7 Research Company Information Table 96. X7 Research Business Overview Table 97. X7 Research Drug Safety and Pharmacovigilance Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. X7 Research Drug Safety and Pharmacovigilance Service Product Portfolio Table 99. X7 Research Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Drug Safety and Pharmacovigilance Service Product Image Figure 2. Global Drug Safety and Pharmacovigilance Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Safety and Pharmacovigilance Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Safety and Pharmacovigilance Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drug Safety Service Image Figure 8. Drug Pharmacovigilance Service Image Figure 9. Global Drug Safety and Pharmacovigilance Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Drug Safety and Pharmacovigilance Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Type (2021-2032) Figure 12. Experimental Stage Image Figure 13. Clinical Stage Image Figure 14. Postmarketing Stage Image Figure 15. Other Image Figure 16. Global Drug Safety and Pharmacovigilance Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drug Safety and Pharmacovigilance Service Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Application (2021-2032) Figure 19. Global Drug Safety and Pharmacovigilance Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drug Safety and Pharmacovigilance Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drug Safety and Pharmacovigilance Service Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drug Safety and Pharmacovigilance Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drug Safety and Pharmacovigilance Service Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drug Safety and Pharmacovigilance Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drug Safety and Pharmacovigilance Service Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drug Safety and Pharmacovigilance Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drug Safety and Pharmacovigilance Service Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drug Safety and Pharmacovigilance Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drug Safety and Pharmacovigilance Service Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drug Safety and Pharmacovigilance Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Drug Safety Service
  • Drug Pharmacovigilance Service
Applications
  • Experimental Stage
  • Clinical Stage
  • Postmarketing Stage
  • Other
Companies covered
  • BioPoint
  • Cmed
  • Drug Safety Solutions
  • Hilbrans
  • Orbis Clinical
  • Parexel
  • PharmaLex
  • ProPharma
  • SGS
  • SJ Pharma Consulting LLC
  • Vitrana
  • X7 Research

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Safety and Pharmacovigilance Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Safety and Pharmacovigilance Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Safety and Pharmacovigilance Service Market Dynamics
  1. 2.1 Drug Safety and Pharmacovigilance Service Industry Trends
  2. 2.2 Drug Safety and Pharmacovigilance Service Industry Drivers
  3. 2.3 Drug Safety and Pharmacovigilance Service Industry Opportunities and Challenges
  4. 2.4 Drug Safety and Pharmacovigilance Service Industry Restraints
3 Drug Safety and Pharmacovigilance Service Market by Company
  1. 3.1 Global Drug Safety and Pharmacovigilance Service Company Revenue Ranking in 2025
  2. 3.2 Global Drug Safety and Pharmacovigilance Service Revenue by Company (2021-2026)
  3. 3.3 Global Drug Safety and Pharmacovigilance Service Company Ranking (2024-2026)
  4. 3.4 Global Drug Safety and Pharmacovigilance Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Safety and Pharmacovigilance Service Company Product Type and Application
  6. 3.6 Global Drug Safety and Pharmacovigilance Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Safety and Pharmacovigilance Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Safety and Pharmacovigilance Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Safety and Pharmacovigilance Service Market by Type
  1. 4.1 Drug Safety and Pharmacovigilance Service Type Introduction
  2. 4.1.1 Drug Safety Service
  3. 4.1.2 Drug Pharmacovigilance Service
  4. 4.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Type
  5. 4.2.1 Global Drug Safety and Pharmacovigilance Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global Drug Safety and Pharmacovigilance Service Sales Value Share by Type (2021-2032)
5 Drug Safety and Pharmacovigilance Service Market by Application
  1. 5.1 Drug Safety and Pharmacovigilance Service Application Introduction
  2. 5.1.1 Experimental Stage
  3. 5.1.2 Clinical Stage
  4. 5.1.3 Postmarketing Stage
  5. 5.1.4 Other
  6. 5.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Application
  7. 5.2.1 Global Drug Safety and Pharmacovigilance Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Drug Safety and Pharmacovigilance Service Sales Value Share by Application (2021-2032)
6 Drug Safety and Pharmacovigilance Service Regional Value Analysis
  1. 6.1 Global Drug Safety and Pharmacovigilance Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Safety and Pharmacovigilance Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Safety and Pharmacovigilance Service Sales Value (2021-2032)
  7. 6.3.2 North America Drug Safety and Pharmacovigilance Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Safety and Pharmacovigilance Service Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Safety and Pharmacovigilance Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Safety and Pharmacovigilance Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Safety and Pharmacovigilance Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Safety and Pharmacovigilance Service Sales Value (2021-2032)
  16. 6.6.2 South America Drug Safety and Pharmacovigilance Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Safety and Pharmacovigilance Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Safety and Pharmacovigilance Service Sales Value Share by Country, 2025 VS 2032
7 Drug Safety and Pharmacovigilance Service Country-level Value Analysis
  1. 7.1 Global Drug Safety and Pharmacovigilance Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Safety and Pharmacovigilance Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Safety and Pharmacovigilance Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Safety and Pharmacovigilance Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Safety and Pharmacovigilance Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Safety and Pharmacovigilance Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BioPoint
  2. 8.1.1 BioPoint Company Information
  3. 8.1.2 BioPoint Business Overview
  4. 8.1.3 BioPoint Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BioPoint Drug Safety and Pharmacovigilance Service Product Portfolio
  6. 8.1.5 BioPoint Recent Developments
  7. 8.2 Cmed
  8. 8.2.1 Cmed Company Information
  9. 8.2.2 Cmed Business Overview
  10. 8.2.3 Cmed Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cmed Drug Safety and Pharmacovigilance Service Product Portfolio
  12. 8.2.5 Cmed Recent Developments
  13. 8.3 Drug Safety Solutions
  14. 8.3.1 Drug Safety Solutions Company Information
  15. 8.3.2 Drug Safety Solutions Business Overview
  16. 8.3.3 Drug Safety Solutions Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Drug Safety Solutions Drug Safety and Pharmacovigilance Service Product Portfolio
  18. 8.3.5 Drug Safety Solutions Recent Developments
  19. 8.4 Hilbrans
  20. 8.4.1 Hilbrans Company Information
  21. 8.4.2 Hilbrans Business Overview
  22. 8.4.3 Hilbrans Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hilbrans Drug Safety and Pharmacovigilance Service Product Portfolio
  24. 8.4.5 Hilbrans Recent Developments
  25. 8.5 Orbis Clinical
  26. 8.5.1 Orbis Clinical Company Information
  27. 8.5.2 Orbis Clinical Business Overview
  28. 8.5.3 Orbis Clinical Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Orbis Clinical Drug Safety and Pharmacovigilance Service Product Portfolio
  30. 8.5.5 Orbis Clinical Recent Developments
  31. 8.6 Parexel
  32. 8.6.1 Parexel Company Information
  33. 8.6.2 Parexel Business Overview
  34. 8.6.3 Parexel Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Parexel Drug Safety and Pharmacovigilance Service Product Portfolio
  36. 8.6.5 Parexel Recent Developments
  37. 8.7 PharmaLex
  38. 8.7.1 PharmaLex Company Information
  39. 8.7.2 PharmaLex Business Overview
  40. 8.7.3 PharmaLex Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PharmaLex Drug Safety and Pharmacovigilance Service Product Portfolio
  42. 8.7.5 PharmaLex Recent Developments
  43. 8.8 ProPharma
  44. 8.8.1 ProPharma Company Information
  45. 8.8.2 ProPharma Business Overview
  46. 8.8.3 ProPharma Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ProPharma Drug Safety and Pharmacovigilance Service Product Portfolio
  48. 8.8.5 ProPharma Recent Developments
  49. 8.9 SGS
  50. 8.9.1 SGS Company Information
  51. 8.9.2 SGS Business Overview
  52. 8.9.3 SGS Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 SGS Drug Safety and Pharmacovigilance Service Product Portfolio
  54. 8.9.5 SGS Recent Developments
  55. 8.10 SJ Pharma Consulting LLC
  56. 8.10.1 SJ Pharma Consulting LLC Company Information
  57. 8.10.2 SJ Pharma Consulting LLC Business Overview
  58. 8.10.3 SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SJ Pharma Consulting LLC Drug Safety and Pharmacovigilance Service Product Portfolio
  60. 8.10.5 SJ Pharma Consulting LLC Recent Developments
  61. 8.11 Vitrana
  62. 8.11.1 Vitrana Company Information
  63. 8.11.2 Vitrana Business Overview
  64. 8.11.3 Vitrana Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Vitrana Drug Safety and Pharmacovigilance Service Product Portfolio
  66. 8.11.5 Vitrana Recent Developments
  67. 8.12 X7 Research
  68. 8.12.1 X7 Research Company Information
  69. 8.12.2 X7 Research Business Overview
  70. 8.12.3 X7 Research Drug Safety and Pharmacovigilance Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 X7 Research Drug Safety and Pharmacovigilance Service Product Portfolio
  72. 8.12.5 X7 Research Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst